Core Viewpoint - The company, Saily Medical, anticipates a net profit loss of between 160 million to 209 million yuan for the entire year of 2025, primarily due to strategic shifts and operational challenges [1]. Group 1: Reasons for Performance Change - The company is focusing on high-quality development by accelerating the construction of an integrated diagnostic and treatment technology platform driven by "AI + Smart Healthcare" and "Innovative Biopharmaceuticals" [2]. - A decline in operating revenue is attributed to the transfer of certain controlling subsidiaries to enhance asset operation efficiency, resulting in these subsidiaries no longer being included in the consolidated financial statements [2]. - The company is undergoing a strategic transformation, with some business contracts not being renewed after expiration, compounded by industry policy impacts, leading to a significant decrease in operating revenue [2]. Group 2: Impact of R&D and Impairments - Increased R&D investment in the smart healthcare sector has negatively impacted profits [3]. - The company has been enhancing its collection efforts on receivables, but extended payment cycles from some clients have led to credit impairment losses [3]. - A decline in revenue and profit from certain subsidiaries has prompted the company to recognize impairment losses on goodwill associated with these subsidiaries [3]. Group 3: Financial Performance Indicators - For the first three quarters of 2025, the company's main revenue was 857 million yuan, a year-on-year decrease of 39.64%, with a net profit attributable to shareholders of -87.24 million yuan, down 55.72% year-on-year [3]. - In Q3 2025, the company reported a single-quarter main revenue of 274 million yuan, a decrease of 38.41% year-on-year, and a net profit attributable to shareholders of -31.12 million yuan, an increase of 39.27% year-on-year [3]. - The company’s financial metrics include a debt ratio of 49.61%, investment income of 7.34 million yuan, financial expenses of 34.98 million yuan, and a gross profit margin of 21.73% [3].

证券之星消息，创新医疗发布业绩预告，预计2025年全年扣除后营业收入:77,600万元至79,600万元。 公告中解释本次业绩变动的原因为： 2、本报告期扣除非经常性损益后的净利润出现同比下降，主要系：在医保政策以及医保支付标准持续 调整的行业背景下，康华医院、建华医院对短期盈利预期的不确定性进行了审慎评估，本报告期确认的 递延所得税资产同比减少，导致所得税费用出现同比上升。 创新医疗2025年三季报显示，前三季度公司主营收入5.97亿元，同比下降2.11%；归母净利润472.44万 元，同比上升116.97%；扣非净利润-2946.98万元，同比上升6.05%；其中2025年第三季度，公司单季度 主营收入1.96亿元，同比下降3.16%；单季度归母净利润1608.57万元，同比上升236.15%；单季度扣非 净利润-1658.58万元，同比下降12.36%；负债率17.84%，投资收益2950.55万元，财务费用60.55万元， 毛利率10.08%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 1、本报告期归属于上市公司股东的 ...

Core Viewpoint - The company is leveraging its resources to enhance international collaboration and provide quality healthcare services to both domestic and overseas patients, with a focus on increasing the proportion of foreign patients in its medical institutions [1] Group 1 - The company has been actively engaging with overseas partners to utilize its comprehensive international hospital advantages [1] - The service volume for foreign patients in the company's medical institutions is currently small but shows a year-on-year increasing trend [1]

声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 第1笔成交价格为51.50元，成交16.00万股，成交金额824.00万元，溢价率为-13.55%，买方营业部为国 泰海通证券股份有限公司杭州学院路证券营业部，卖方营业部为中国银河证券股份有限公司北京苏州街 证券营业部。 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为824万元。该股近5个交易日累计下 跌5.40%，主力资金合计净流出2038.53万元。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 1月29日，美迪西收涨1.41%，收盘价为59.57元，发生1笔大宗交易，合计成交量16万股，成交金额824 万元。 ...

Core Viewpoint - The company, MediTech (603990.SH), expects a net profit attributable to shareholders of the parent company to be between 39 million and 44 million yuan for 2025, with a net profit excluding non-recurring gains and losses projected to be between 10 million and 15 million yuan [1] Group 1 - The main reason for the turnaround to profitability is the impact of the photovoltaic business, which resulted in a negative net profit for 2024 [1] - In 2025, the company plans to complete a significant asset sale to divest from the photovoltaic business [1] - The company is focusing on three strategic initiatives: concentrating on the medical core business, enhancing asset-light attributes, and building a platform-based ecosystem to optimize its business structure and improve operational stability [1] Group 2 - The company aims to enhance its profitability through refined management practices, continuously improving operational efficiency and cost control [1]

报告期归属于上市公司股东的净利润出现同比上升，主要系：公司增持博灵脑机股权并将该公司纳入合 并报表范围，根据《企业会计准则第33号——合并财务报表》第四十八条的规定，确认了相应的投资收 益；李晔案件再审改判后，建华医院收到了法院返还的被执行款项，并由此确认了营业外收入。 格隆汇1月29日丨创新医疗(002173.SZ)公布2025年度业绩预告，预计2025年度净亏损2,600万元-3,300万 元，上年同期亏损9,395.40万元；预计2025年度扣非净亏损6,800万元-7,500万元，上年同期5,957.41万 元。 报告期扣除非经常性损益后的净利润出现同比下降，主要系：在医保政策以及医保支付标准持续调整的 行业背景下，康华医院、建华医院对短期盈利预期的不确定性进行了审慎评估，本报告期确认的递延所 得税资产同比减少，导致所得税费用出现同比上升。 ...

泰格医药(300347.SZ)公告称，预计2025年归属于上市公司股东的净利润为8.30亿元–12.30亿元，比上年 同期增长105%–204%。业绩变动主要系报告期内非经常性损益大幅增加，公司持有的非流动金融资产 （包括非上市公司股权、上市公司股份及医药基金）处置及持有收益显著提升，叠加中国创新药行业复 苏带动资产价值修复。公司的新签订单数量和金额均较去年同期实现较好增长。2025年，公司净新增订 单（新签订单剔除取消订单后）区间为人民币95亿元至人民币105亿元，2024年同期净新增订单为人民 币84.20亿元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

（记者 王晓波） 每经AI快讯，创新医疗1月29日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润为-2600万 元至-3300万元，基本每股收益-0.06元至-0.07元。上年同期净利润为-9395.4万元。 每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

Group 1 - The company, Da Dongfang, expects to report a net loss attributable to shareholders of the parent company between -235 million and -175 million yuan for the year 2025, indicating a decline compared to the same period last year [1] - The main reason for the performance change is the continued strengthening of the department store business's招商力度, enhancing advantageous categories, optimizing consumer scenarios, upgrading customer experience, and intensifying holiday marketing and membership management, despite a slight decline in revenue and gross profit due to a downturn in consumer spending and the impact of traditional retail channels [1] - The pediatric medical business is focusing on the development of existing business while actively expanding new disciplines and products, leading to a decline in revenue but an increase in gross profit, with profits maintaining growth year-on-year and core business operations remaining stable [1] Group 2 - The investigation into the "Jie Wo Rui" redemption crisis on the Shuibei Gold platform reveals a 40-fold leverage bet, where the platform incurs losses as gold prices rise, with the owner claiming to still be in Shenzhen [1]

Core Viewpoint - The company, Saily Medical, is expected to report a significant net loss for the year 2025, with projections indicating a loss between 160 million to 209 million RMB for net profit attributable to shareholders, and a loss between 180 million to 230 million RMB for net profit after deducting non-recurring gains and losses. This downturn is primarily attributed to a decline in operating revenue and increased R&D expenditures in the smart medical field [1][2]. Group 1: Financial Projections - The estimated net profit attributable to shareholders for 2025 is projected to be between -160 million to -209 million RMB [1] - The estimated net profit after deducting non-recurring gains and losses for 2025 is projected to be between -180 million to -230 million RMB [1] Group 2: Reasons for Performance Decline - The decline in operating revenue is due to the company's strategic decision to focus on core business development, resulting in the transfer of certain subsidiaries, which will no longer be included in the consolidated financial statements [1] - The company is undergoing a strategic transformation, and the lack of renewal arrangements for certain business contracts, combined with industry policy impacts, has led to a decrease in operating revenue [1] - Increased R&D investments in the smart medical field have negatively impacted profits due to higher R&D expenses [2]